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In the recent years, the discovery of a series of mutations in patients with myeloid malignancies has provided insight into the
pathogenesis of myelodysplastic syndromes (MDSs), myeloproliferative neoplasms (MPNs), and acute myeloid leukemia (AML).
Among these alterations have been mutations in genes, such as IDH1/2, TET2, DNMT3A,a n dEZH2,w h i c ha p p e a rt oa ﬀect DNA
and/or histone lysine methylation. Large clinical correlative studies are beginning to decipher the clinical importance, prevalence,
and potential prognostic signiﬁcance of these mutations. Additionally, burgeoning insight into the role of epigenetics in the
pathogenesis of myeloid malignancies has prompted increased interest in development of novel therapies which target DNA and
histone posttranslational modiﬁcations. DNA demethylating agents have been demonstrated to be clinically active in a subset
of patients with MDS and AML and are used extensively. However, newer, more speciﬁc agents which alter DNA and histone
modiﬁcation are under preclinical study and development and are likely to expand our therapeutic options for these diseases in
the near future. Here, we review the current understanding of the clinical importance of these newly discovered mutations in AML
and MDS patients. We also discuss exciting developments in DNA methyltransferase inhibitor strategies and the prospect of novel
histone lysine methyltransferase inhibitors.
1.Introduction
The increasing use of systematic genome-wide discovery
eﬀorts in patients with a variety of myeloid malignancies has
led to the rapid discovery of a series of recurrent genetic
abnormalities underlying these disorders. Remarkably, a
large number of these alterations appear to be in genes
whose function is known, or suspected, to be involved in
epigenetic regulation of gene transcription. In the last 3
years, alone mutations in the genes TET2, IDH1, IDH2,
DNMT3a,a n dEZH2 have all been found in patients
with myeloproliferative neoplasms (MPNs), myelodysplas-
tic syndromes (MDSs), and/or acute myeloid leukemia
(AML). Although the functional implications of these
mutations and how precisely they contribute to abnormal
hematopoiesis and leukemogenesis is being heavily investi-
gated and not yet clariﬁed, a number of potentially clinically
important implications of these mutations may already be
apparent. First, mutations in several of these genes likely
hold prognostic importance for patients, and these genetic
alterations, thereby, may serve as prognostic markers for
risk stratiﬁcation and aid in therapeutic decision making.
Secondly, mutations in several of these genes may speciﬁcally
impact DNA methylation and/or histone posttranslational
modiﬁcations in such a manner that is therapeutically
targetable. Mutations in several of these genes, such as IDH1
and IDH2, have been proven to result in a gain-of-enzymatic
function which holds the prospect for development of novel
targeted therapeutics. This review focuses on the clinical
relevance of recently discovered epigenetic alterations in2 Advances in Hematology
patients with myeloid malignancies and the prospect for
novel targeted therapeutics against aberrant epigenomic
characteristics in patients with MDS and AML.
2. Recently Identiﬁed Mutationsin
EpigeneticModiﬁersinMyeloidMalignancies
2.1. IDH1 and IDH2 Mutations. Genome sequencing of
AML has recently led to the discovery of mutations in
the genes encoding isocitrate dehydrogenase (IDH1 and
IDH2). IDH1 is a key cytosolic enzyme in the Krebs cycle.
It catalyzes the decarboxylation of isocitrate to α keto-
glutarate (α-KG), leading to the production of nicotinamide
adenine dinucleotide phosphate (NAD-P). The isocitrate
dehydrogenase2(IDH2)geneencodesahomologousprotein
which catalyzes the same reaction in mitochondria. IDH
mutations have been extensively studied and are frequently
found alterations in low-grade gliomas. They have also
been discovered in a small subset of the highly aggressive
glioblastomas, where they confer a more favorable prognosis
[1–6].
IDH mutations were subsequently identiﬁed in AML
and other myeloid malignancies, including MDS and MPNs
[7, 8]. All discovered IDH mutations reside in the active site
of the enzyme and participate in isocitrate binding [9]. They
are missense alterations aﬀecting arginine-132 (R132) in
IDH1, and either the analogous arginine residue (R172), or
the arginine-140 (R140) residue in the IDH2 protein [7, 10–
15] .T h ec o m m o nr e c u r r e n c eo fIDH mutations in AML
suggests an importance in leukemogenesis. All mutations are
missense and heterozygous, suggesting that the alterations
lead to a “gain of function” [9]. It has been shown that
the mutant forms of IDH cannot catalyze the conversion of
isocitrate to α-KG [16]. Dang et al. reported that the mutated
R132H IDH1, in place of the normal process of isocitrate
decarboxylation, catalyzes an NADPH-dependent reduction
of α-KG to 2-hydroxyglutarate (2-HG). 2-HG is a metabolite
which is normally present at very low levels in cells [17], 2-
HG levels have been found to be elevated in IDH-mutant
glioma samples, and Gross et al. reported that IDH1 R132
mutations also lead to production and accumulation of 2-
HG in AML blasts, greater than 50-fold higher than their
nonmutant counterparts. Elevated 2-HG levels in IDH-WT
samples led to the ﬁrst discovery of IDH2 mutations, which
accounted for elevated 2-HG levels in these AML cells. The
elevation in 2-HG levels has also been noted in sera of
patients with IDH-mutant AML [9].
Studies of IDH mutations in gliomas have suggested that
they are an early event in the pathogenic process [5]. Their
exact mechanism in leukemogenesis of AML is uncertain.
Normal IDH function appears essential for normal cell
growth and proliferation. IDH1 is one of only three cytosolic
proteins which contribute to NADPH production which
is essential for nucleotide and lipid synthesis. Ward et al.
demonstrated that siRNA silencing of the IDH1 and IDH2
proteins led to a signiﬁcantly reduced proliferative capacity
[15]. Some investigators have suggested that accumulation
of 2-HG plays an important role in this process, the “gain of
function” neomorphic enzyme activity that promotes cancer
[9, 18, 19]. Patients with a rare inherited condition called 2-
hydroxyglutaric aciduria have elevated levels of 2-HG with
an increased propensity for brain tumors. 2-HG has indeed
been shown to increase reactive oxygen species in these
patients [20, 21]. Additionally, 2-HG is homologous to α-KG
in structure and thus may bind and interfere with essential
enzymes that are activated by α-KG. Among these are prolyl
hydroxylases which control the stability of and downregulate
HIF-1α transcription factors, implicated in the pathogenesis
of multiple malignancies [9, 19, 22].
The association of IDH mutations with aberrant hyper-
methylation has only recently been discovered. By studying
samples from 398 AML patients in an Easter Cooperative
Group (ECOG) E1900 trial, we found that IDH-mutant
AML is associated with consistent and aberrant hyperme-
thylation of various promoter sites involved in myeloid dif-
ferentiation and leukemogenesis [23]( Figure 1). Promoter
CpG sites are extremely important in the regulation of gene
expression, speciﬁcally those of genes which mediate tumor
suppression and diﬀerentiation, and DNA methylation can
lead to transcriptional inactivation or chromosomal instabil-
ity [24, 25]. Aberrant hypermethylation has been extensive
described as a pathogenic process in forms of MDS and
AML [26–29]. The discovery of aberrant hypermethylation
and transcriptional inactivation of loci in relation to IDH-
mutant AML is intriguing and signiﬁcant. The potential
mechanism for the hypermethylation and leukemogenesis in
IDH-mutant disease may be related to downregulation of
normal α-KG levels. Multiple enzymes are dependent on α-
KG for their function, including the TET enzymes, which
appear to play an important role in the diﬀerentiation of
myeloid cells and promote demethylation by hydroxylating
methylcytosine groups [30, 31].
Another recent study reported that altered 2-HG/α-KG
levels present in IDH1/2 mutant cells additionally results in
the inhibition of a diﬀerent set of α-KG-dependent enzymes,
the Jumonji family of histone lysine demethylases (JHDM)
[32]. There are 3 classes of enzymes which are known to
antagonize histone methylation: (1) peptidylarginine deim-
inase, which removes methylarginine modiﬁcations to pro-
duce citrulline [33], (2) lysine speciﬁc demethylase 1 which
removes H3K4me1/H3K9me1 marks in a reaction requiring
ﬂavin is a cofactor [34], and the Jumonji C domain family
of histone demethylases which require iron Fe(II) and α-KG
as cofactors. Unlike LSD1, which can only remove mono-
and dimethyl lysine modiﬁcations, the JHDMs can remove
methyl groups from all three histone methylation states.
So far, JHDM family members have been shown to reverse
the following lysine methyl marks: H3K36me1/2 (JHDM1)
[35], H3K9me1/2 (JHDM2) [36], H3K9me2/3 (JHDM3)
[35], and H3K36me3 (JHDM3) [35], H3K4me2/3 (JARID1)
[37], and H3K27me2/3 (UTX/JMJD3) [38]. In addition,
JMJD6 has been shown to encode an arginine-speciﬁc
histone demethylase which demethylates H3R2me1/2 and
H4R3me1/2 [39]. All of these marks may, therefore, be
aﬀected by the presence of IDH1/2 mutations, and Xu
et al. indeed demonstrated hypermethylation of many of
these marks following introduction of IDH1/2 mutations
into cells [32]( Figure 1). These ﬁndings lend signiﬁcantAdvances in Hematology 3
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Figure 1: Speciﬁc histone and DNA posttranslational modiﬁcations shown to be associated with mutations in epigenetic modiﬁers in
hematologic malignancies. Only genetic alterations which have some evidence for resulting in a gain or loss of function are displayed
here. Mutations which result in the acquisition of hyperactivation or new enzymatic activity are displayed on the left of nucleosome while
mutations which have evidence as resulting in a loss of enzymatic function are displayed on the right (translocations known to directly aﬀect
histone posttranslational modiﬁcations are listed in Table 1). The majority of mutations in epigenetic modiﬁers in myeloid malignancies
recently identiﬁed are known to aﬀect posttranslational modiﬁcations on the N-terminal tail of histone H3 or at cytosines of DNA as
displayed here. Currently, the function of DNMT3a mutations in AML has yet to be extensively clariﬁed, particularly the recurrent R882
heterozygous mutations.
credence to the theory that hypermethylation of DNA and
histone lysine/arginine modiﬁcations play a key role in the
pathogenesis of AML in this subgroup of patients. Further
work to delineate the complex epigenetic alterations to the
transcriptional changes which promote leukemogenesis will
be very enlightening.
Currently, our clinical use of genetics in AML for prog-
nostication relies on (1) the use of cytogenetics to delineate
patients into favorable, intermediate, or adverse cytogenetic
categories and (2) molecular genotype of the genes FLT3,
NPM1 (nucleophosmin 1),a n dCEBPA (CCAAT/enhancer-
binding protein alpha) for those patients with a normal
karyotype. Multiple studies have demonstrated that patients
with a normal karyotype but with an internal tandem
duplication of FLT3 (FLT3-ITD) have an inferior outcome
comparedtothosewithoutaFLT3-ITDmutation[40,41].In
severaladditionalstudies,thepresenceofanNPM1mutation
with or without the presence of a FLT3-ITD mutation was
associated with higher complete response and event-free
survival [42, 43]. Normal karyotype AML with mutations
in CEBPA also appear to represent a subset of AML with
more favorable outcome [44, 45]. Given the identiﬁcation
of multiple new molecular genetic abnormalities in patients
with AML, an increasing number of studies have been per-
formedtodelineatethemutationalfrequencyandprognostic
implications of IDH1/2, TET2,a n dDNMT3A mutations in
AML patients. The initial report of IDH1 mutations in AML
found that 8.5% of AML samples contained a mutation at
aminoacidR132.Allmutationswereassociatedwithsamples
that displayed intermediate risk cytogenetics, with the large
majority having normal cytogenetics. With this relatively
small group of 187 samples, the investigators noted no
independent prognostic value on overall survival (OS), but
subgroup analysis suggested adverse eﬀects in those patients
with no NPM1 mutations [7]. Ward et al. also assessed for
mutationsinaseriesof87AMLsamplesandfoundthat7.7%
had IDH1 mutations. Additionally, they found that even a
larger subset of samples (15.4%) displayed mutations in the
IDH2 gene. All samples with IDH mutations were found to
havenormalkaryotypes,withoutaneﬀectonoverallsurvival
[15].
Larger studies, based in North America and Europe,
have attempted to further investigate the prevalence and
prognostic implications of these mutations. A CALGB
study assessed bone marrow and peripheral blood marrow
samplesfrom358patientswithcytogeneticallynormalAML.
The investigators reported IDH mutations in the third
of their patients, with 14% having IDH1 mutations and
19% displaying IDH2 mutations. AML patients with IDH
mutations in this study tended to be younger with lower-
risk disease as deﬁned by a higher frequency of NPM1
mutations without the presence of FLT3-ITD mutations.4 Advances in Hematology
Speciﬁcally, IDH1 mutations adversely aﬀected disease-free
survival (DFS) in this particular subgroup of patients with a
favorable molecular proﬁle. Interestingly, those patients with
IDH2 mutations achieved a lower rate of complete remission
with induction therapy [12].
A study from The Netherlands also found a signiﬁ-
cant prevalence of IDH mutations in 893 samples from
patients with newly diagnosed AML, with 6% and 11%
having IDH1 and IDH2 mutations, respectively. They also
reported an association with normal karyotype AML and
the NPM1 mutation. As in previous studies, no eﬀect on
OS was noted for the entire cohort of AML samples, but
interestingly, in those samples without an NPM1 mutation,
IDH mutations were associated with an inferior event-free
survival (EFS) [10]. A subsequent study from the UK found
IDH1 mutations in 8% of patient samples, using data on
1333 adult patients from the UK MRC AML10 and AML12
trials. Similar to the Dutch study, they reported a strong
association with intermediate cytogenetics and the NPM1
mutation. However, in contrast to the previous study but
similar to results of the CALGB trial by Marcucci et al. [12],
the investigators found that an IDH1 mutation preferentially
reduced survival in the cohort of patients with a coexistent
NPM1 mutation [46]. These ﬁndings were supported by
large studies from France and Germany, which again found
that 12–16% of patients had IDH mutations, with the
mutations adversely aﬀecting rates of CR and survival in
the subgroup of patients with CN-AML and with NPM1
mutations [11, 13].
However, the prognostic signiﬁcance of the copresence
of IDH and NPM1 mutations in CN-AML continues to be
uncertain. A recent large German study reported shorter EFS
and rates of CR in all AML patients with an IDH1 mutation,
and speciﬁcally within the population of patients without
NPM1 mutations [14]. The same authors have recently also
presented their data at the annual American Society of
Hematology (ASH) 2010 meeting on 526 patients with cyto-
genetically normal AML and found that 28.7% of patients
had IDH mutations. 12.9% of patients were found to have
IDH1 mutations and 15.8% had IDH2 mutations. In their
survivalanalysis,noeﬀectwasfoundonOSorEFS.However,
in this presentation, a trend for shorter EFS was reported in
all IDH mutant patients with NPM1+/FLT3-ITD genotype,
and, interestingly, a signiﬁcant adverse eﬀect on EFS in those
with speciﬁcally IDH2 mutations in the NPM1+/FLT3-ITD-
group [47]. The leukemia group from M.D. Anderson in
Houston, Tex, USA, also presented their data at the ASH
2010 meeting on 358 AML patients treated with induction
chemotherapy. They found that IDH1 and IDH2 mutations
wereassociatedwithnormalkaryotypeandNPM1mutations
and were present in 12 (7%) and 24 (14%) patients and
also found an IDH1G105 single-nucleotide polymorphism
(SNP) alteration in 24 (14%) patients. Overall, they found
that 30% of patients had IDH alterations, but there was no
association with achievement of CR, remission duration, OS
or EFS, and IDH aberrations [48]. Caramazza et al. from the
Mayo Clinic examined IDH mutations in 157 patients with
hematologic malignancies and suggested an association with
isolated trisomy 8. Eighteen IDH mutations were identiﬁed,
with the majority (15) being IDH2 mutations. Seventeen of
the 18 IDH mutations occurred in myeloid malignancies,
among which the large majority were MDS or AML. IDH
mutations were fewer among 64 additional patients with
AML or MDS without isolated trisomy 8. In MDS patients
with trisomy 8 alteration, prognosis was similar between
those with IDH mutations and those without [49].
2.2. TET2 Mutations. TET2, the ten-eleven-translocation
gene 2, is located in chromosome 4 at band 4q24. Del-
hommeau and colleagues ﬁrst described the presence of
TET2 mutations in myeloid malignancies, by evaluating
bone marrow samples from 320 patients with MDS, MPNs,
and AML. TET2 defects, either mutations or deletions,
were discovered in 17 of 90 patients with MDS (19%),
in 24 of 198 patients with MPN (12%), and in 5 of 21
patientswithsecondaryAML(24%) [50].Othergroupshave
since reported a similar prevalence of TET2 mutations in
myelodysplastic syndromes and other myeloid diseases [51–
53]. TET2 mutations were also found in the large majority
(median of 96%) of the precursor cells in the bone marrow
ofpatientswithmutations,includingCD34+progenitorcells
[54]. In addition, there has also been much interest in the
role of TET2 as a transformative mutation in myelodysplasia
and MPNs. By analyzing the DNA of paired samples from
patients with transformed, secondary AML, it was found
that TET2 mutations were detected most frequently after the
transformation of MPNs to AML [55].
The pathogenic mechanism of TET2 mutations in
myeloid diseases has been an area of intense investigation.
Strong evidence supports the integral role of TET2 in
demethylationofDNAandepigeneticregulation,speciﬁcally
in the conversion of 5-methylcytosine to 5-hydroxymethyl-
cytosine (5-hmC) [30, 31]. A recent intriguing study con-
vincinglydemonstratedthat5-hmCisanintermediaryinthe
process of DNA demethylation, and that TET hydroxylases
are essential mediators of this process [56]. Ko et al. further
demonstrated that mutations of TET2 lead to alteration
and suppression of catalytic activity of the enzyme. They
reported low DNA levels of 5-hmC in bone marrow samples
taken from patients with TET2 mutations. In addition, the
depletion of TET2 in murine models led to a suppression of
diﬀerentiation of hematopoietic precursors in culture [57].
Thisinterruptioninmyelopoiesismaybeanecessary“hit”or
alteration in the process of leukemogenesis in patients with
TET-2 mutant AML.
Most recently, a variety of groups have studied the
prognostic impact of TET2 mutations in MDS and AML.
Theyappeartohaveaparticularlyhighprevalenceinchronic
myelomonocytic leukemias, in which they have been found
to be associated with signiﬁcant monocytosis and poor
outcomes [58]. Data on prognosis has also been presented
in patients with MDS and AML, where there has been some
controversy.Niboureletal.sequencedsampleDNAfrom111
patients who had achieved CR after induction chemotherapy
for de novo AML. They reported an overall incidence of
17% of TET2 mutations, which were associated with NPM1
mutations but did not appear to have an impact on survival.
This lack of eﬀect on outcomes was also reported by otherAdvances in Hematology 5
investigators [59, 60]. Another group from France reported
that TET2 mutations were actually independently associated
with signiﬁcantly improved overall and progression-free
survival in patients with MDS. Only a small percentage of
patients (7%) in this study were reported to have secondary
AML [61]. In contrast, other investigators have reported a
signiﬁcant adverse eﬀect on overall survival in patients with
AML [51], and a recent CALGB report of 427 patients with
cytogenetically normal AML found that TET2 mutations
were associated with a lower rate of CR and shorter disease-
free and overall survival, with outcomes particularly worse
for patients with favorable risk (CEPBA and NPM1 mutant)
disease [62].
Perhaps, more intriguing has been the consistent ﬁnding
in recent studies that TET2 mutations rarely cooccur with
mutations aﬀecting isocitrate dehydrogenase (IDH1 and
IDH2)[ 60, 62]. As mentioned, the possible mechanism for
aberrant methylation and leukemogenesis in IDH-mutant
AMLmayberelatedtothedownregulationofα-KGlevels,on
which TET2 enzymes depend for their activity [26]. Others
have reported that the metabolite 2-HG, markedly elevated
in samples of patients with IDH mutant AML, can also
directly inhibit TET2 function [32]. Therefore, TET2 and
IDH mutations may be leukemogenic through a common
mechanism, that of suppression of TET2 function. They,
thus, likely act as a distinct mutational class in AML with
overlappingeﬀectsonDNAmethylationandleukemogenesis
(Figure 1).
2.3. DNMT3A Mutations. DNA methyltransferases catalyze
the methylation of cytosine residues of CpG dinucleotides
in DNA and are encoded by the human genes DNMT1,
DNMT3A,andDNMT3B.DNMT3AmutationsinAMLhave
onlybeenrecentlydescribed[63–65]andfoundtobepresent
in approximately 20–22% of patients with de novo AML.
Interestingly, these mutations seem to be associated with
intermediate-risk AML, a ﬁnding also noted with TET2-a n d
IDH-mutant disease. In contrast, no cases of favorable risk
AML contained these mutations [63]. Unlike the exclusivity
of TET2 and IDH m u t a t i o n si nr e c e n ts t u d i e so fA M L ,
DNMT3A mutations often cooccurred with IDH mutations,
suggesting that these latter two mutations may not have
overlapping functions in leukemogenesis.
Somatic mutations in DNMT3A have been reported as
nonsense, frameshift, and missense mutations throughout
the open-reading frame. However, a notable recurrent
mutation in DNMT3A has been repeatedly reported in
AML [63]a n dM D S[ 66] patients as a somatic missense
mutation at amino acid R882. Although one study reported
a decrease in DNA methylation activity of >50% with the
DNMT3A R882 mutant [64]i na nin vitro methyltransferase
assay, AML patient samples with DNMT3a mutations were
not found to have altered total 5-methylcytosine content
or altered patterns of methylation [63]( Figure 1). Equally
important is the fact that the DNMT3A R882A mutation
appears to occur exclusively as a heterozygous mutation
suggesting a potential gain of function which may or may
not require a wildtype copy of DNMT3a for altered function.
Future studies examining the function of the DNMT3A R882
mutation in vitro and in vivo in the presence of wildtype
DNMT3A will hopefully shed further light on a pathogenic
mechanism of DNMT3a mutations in AML.
DNMT3Amutationsweresubsequentlynotedinpatients
with MDS and secondary AML. Walter et al., sequenc-
ing samples from 150 patients, found that 12 harbored
DNMT3A mutations. Similar to the trend noted in AML,
the majority of mutations were at amino acid R882. These
mutations were associated with worse overall survival and
rapid progression to AML, although sample size was small
and transplantation status was not considered [66]. The
adverse impact on survival has also been reported in patients
with AML. Ley and colleagues found, in their cohort, that
those with DNMT3A mutations experienced a signiﬁcantly
worse median overall survival of 12.3 months as compared
to 41.1 months for those without mutations. Interestingly,
it appeared that DNMT3A mutations accounted for the
majority of the adverse eﬀe c to ns u r v i v a ls e e ne v e ni n
patients with FLT3-ITD alterations [63]. A more recent
study from China, studying patients with acute monocytic
leukemias,alsoreporteddecreasedoverallsurvivalandworse
outcomes in those with DNMT3A mutations [65]. Lastly,
DNMT3a mutations have also recently been reported in
patients with primary myeloﬁbrosis [67]. Larger studies
of DNMT3a mutations in patients with additional MPNs
will be needed to further understand the clinical and/or
prognostic importance of DNMT3a mutations in MPNs.
2.4. EZH2 Mutations. EZH2 is a highly conserved enzyme
which serves as a histone H3 lysine 27 (H3K27) methyltrans-
ferase. Although EZH2 has been known to be overexpressed
in several epithelial malignancies for some time, only in
2010 was it discovered that EZH2 may be mutated in
hematopoietic malignancies. Curiously, a recurrent mono-
allelic activating mutation has been identiﬁed in EZH2 at
tyrosine 641 in patients with lymphomas [68] while a series
of apparent loss-of-function mutations have been found in
patients with MDS and primary myeloﬁbrosis [69–71].
ThefactthatEZH2isalteredbyoverexpression/increased
activity in epithelial cancers and lymphomas, yet inactivated
in myeloid malignancy, argues that the biologic conse-
quences of alterations in H3K27me3 may be tissue speciﬁc.
At the same time, rigorous assessment of whether EZH2
mutations aﬀect the abundance and/or the distribution of
H3K27me3 inthechromatinofmalignantversuspaired nor-
mal nonmutated cells has not yet been published (Figure 1).
In addition, investigation of the eﬀects of EZH2 mutations
on alterations in DNA methylation may be particularly
important given that EZH2 physically interacts with DNA
methyltransferases 1–3 [72], and data suggests that H3K27
methylation is a necessary prerequisite for DNA promoter
methylation [72].
From a clinical standpoint, inactivation of EZH2 by
loss or mutation in MDS is enlightening as cytogenetic
abnormalities of chromosome 7 which have been long
recognized in MDS and AML and linked to adverse outcome
[73, 74]. In fact, several studies suggest that MDS patients
with EZH2 mutations have worsened overall survival com-
pared to those without EZH2 mutations, regardless of gross6 Advances in Hematology
cytogenetic ﬁndings [70, 71]. Larger studies incorporating
EZH2 mutations in light of additional genetic abnormalities
will be needed to further clarify the prognostic importance
of EZH2 mutations in MDS and MPNs and are ongoing.
3.TheProspectofNovelTherapeutic
Agents Targeting EpigeneticModiﬁers
inMyeloidMalignancies
3.1. DNA Methyltransferase Inhibitors (DNMTIs). The ﬁrst
three epigenetic targeted therapeutics which have been FDA
approved for use in the United States include 2 drugs
targeting DNMTs (azacitidine (AZA) and decitabine (5-
aza-2 -deoxycytidine)) as well as one histone deacetylase
inhibitor (vorinostat). Although the use of DNMTIs has
proven useful in the therapy of high-risk MDS as well as
in AML, there are several questions which have lingered
regarding theuse of thesetherapies: (1) whatis the idealdose
and schedule of DNMTIs? (2) what is the true mechanism of
action of the nucleoside DNMTIs? (3) are there biomarkers
which can be used for predicting response and/or resistance
to DNMTIs? and (4) can we develop nonnucleoside direct
inhibitors of DNMTs?
Despite questions regarding use and schedule of
DNMTIs, there have been several interesting new devel-
opments in this class of therapeutics. Within the original
category of nucleoside analog DNMTIs, an oral formulation
of AZA has recently been developed [75]. Parenteral azaciti-
dine is approved for administration at 75mg/m2 for 7 days
every 28 days, and this dose is believed to result in DNA
hypomethylation as well as cytotoxicity. Using several assays
for DNA methylation, this dose of 5-aza has been shown to
result in maximal DNA hypomethylation at approximately
day 15 with gradual return of DNA methylation back to
baseline around the time of next cycle [76]. Given this, use of
orally administered AZA on a more frequent schedule may
result in altered eﬀects on DNA methylation and cellular
cytotoxicity and holds the potential for greater therapeutic
eﬃcacy. The initial phase I trial of oral AZA on a 7 days
schedule revealed that the drug is bioavailable, safe, and
clinically active in patients with MDS and AML. At the 2010
ASH meeting, results of the multicenter phase I study of
extended oral AZA schedules revealed that oral azacitidine
on a 14- or 21-day schedule is well tolerated, with no
AZA accumulation, and promising clinical responses were
observed [75].
The direct cytotoxic eﬀects of the clinically utilizing
DNMTIs as well as their chemical instability have prompted
continuous rationale for developing additional DNMTIs. A
thirdnucleosideDNMTIwhichhasbeenunderdevelopment
for some time is the cytidine analogue zebularine. Although
zebularine has a similar mechanism of action as decitabine
andazacitidine,resultinginthedepletionofDNMTsthrough
covalent bonding with DNMTs, zebularine has a much
longer half-life making oral administration of the drug
possible [77, 78]. Additionally, zebularine appears to be
selectively incorporated into malignant and not normal cells
admixed with tumor in at least one setting, a property not
seen with decitabine or AZA [79]. Despite these properties,
one limitation to the development of zebularine for clinical
usehasbeenthefactthathigherconcentrationsofzebularine
are needed to obtain similar levels of demethylation in cells
in comparison with azacitidine and decitabine [78]. Further
preclinical works addressing the practicality of the drug as a
clinical therapeutic agent are ongoing.
In addition to the nucleoside DNMTIs, there has been
considerable eﬀorts at developing nonnucleoside targeted
molecules to directly inhibit individual DNMTs. One
approach has been the development of antisense oligonu-
cleotides targeting DNMT1 for in vivo use. One such
molecule, the phosphorothioate antisense oligonucleotide
MG98, was developed based on its ability to knockdown
DNMT1 expression in various model systems [80, 81].
However, phase I clinical trials of MG98 in solid and
hematopoietic tumors was disappointing with very little
consistent knock down of DNMT1 mRNA in patients [82,
83]. This likely resulted from ineﬃcient intracellular uptake
of MG98.
Rational design of small molecules targeting DNMTs
through noncovalent interactions with the catalytic sites of
these enzymes has resulted in the development and char-
acterization of several test compounds. The ﬁrst rationally
designed DNMT1 inhibitor is RG108 which was designed
utilizing a three-dimensional model of the human DNMT1
catalytic pocket [84]. RG108 has comparable demethylating
activity to zebularine but appears to be less active than azac-
itidine and decitabine. Several additional small-molecular
inhibitors of DNMTs have more recently been found within
the NCI open database of compounds through a similar
screening approach which led to the discovery of RG108
[85]. Further preclinical characterization of all of these
compounds is underway.
The use of DNMTIs in patients with high-risk MDS and
AML has proven that while durable complete remissions are
possible with these drugs, responses can be quite variable
with no current routinely used clinical parameter known
to predict likelihood of response to therapy. With the
discovery of mutations in TET2 in these patients and the
postulated pathogenic mechanism of TET2 mutations in
MDS/AML, it has been hypothesized that TET2-mutated
patients may have higher rates of response to DNMTIs. This
has recently been suggested by a small French study of 86
patients with MDS and secondary AML. The investigators
reported that those with TET2 mutations experienced a
response rate (RR) of 82% to AZA in comparison to the
TET2-wt group, which had a signiﬁcantly lower RR of 45%.
However, there was no eﬀect on survival parameters, and
the study group was quite heterogeneous with few additional
genetic parameters studied [86]. In contrast, other groups
have found that TET2 alterations in a similar cohort of
patients may actually predict for decreased responsiveness
to demethylating therapies [87]. The small number of
patients included in these studies and the limited genetic
characterization of the patients must be considered. Larger
studies with more comprehensive genetic evaluation will
be critical in determining if mutations in genetic factors
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(TET2, IDH1/2,a n dDNMT3a mutations, amongst others)
aﬀect response to DNMTIs.
4. The Prospect for Novel Histone
Methyltransferase Inhibitorsin
Myeloid Leukemias: DOT1L
Inhibition andRationalDesign of
ProteinMethyltransferaseInhibitors
Recent discovery of the potential importance of aberrant
hypermethylation of histone lysines in the pathogenesis
of myeloid leukemias driven by MLL-translocations [88],
NUP98-NSD1 translocations [89], and possibly IDH1/2-
mutant disorders [32] suggests the possibly of targeting
histone lysine methyltransferases in myeloid leukemias.
One novel and exciting prospect utilizing this therapeu-
tic rationale is the study of DOT1L-targeted therapy for
the selective treatment of MLL-translocated leukemias. In
addition to the recently identiﬁed mutations in epigenetic
modiﬁers in MDS and AML, a number of translocations
disrupting the normal activity of epigenetic modiﬁers in
myeloid malignancies have been recognized for a longer
periodoftime(Table 1).Keyamongstthefrequenttransloca-
tions altering the activity of an epigenetic modiﬁers in AML
includes translocations involving mixed lineage leukemia 1
(MLL1) which occur in at least 10% of adult AML patients
and >70% of infant acute leukemias. MLL1 normally serves
as an histone H3 lysine 4 (H3K4) methyltransferase. MLL1
translocations result in fusion of the N terminus of MLL1
to one of >60 diﬀerent translocation partners [90]. In a
recent landmark survey of MLL rearrangements, 760 MLL-
rearranged biopsy samples were reviewed and 104 diﬀerent
MLLrearrangementswerefoundinadultandpediatricacute
leukemia patients [90]. However, amongst AML patients
with MLL rearrangements, 77% were accounted for by
one of 7 translocations: MLL-AF9 (30.4%), MLL-AF10
(14.5%), MLL-ELL (10.9%), MLL-AF6 (10.1%), MLL-ENL
(5.4%), MLL-AF17 (2.9%), and MLL-SEPT6 (2.5%). Many
ofthesesameMLLrearrangementsarealsocommoninacute
lymphoblasticleukemia(ALL)alongwithMLL-AF4whichis
the most common MLL rearrangement in ALL (accounting
for 66% of MLL-rearranged ALL cases) [90].
Importantly, the four most frequent MLL translocations
(MLL-AF4, MLL-AF9, MLL-AF10, and MLL-ENL) result in
recruitment of DOT1L (disruptor of telomeric silencing 1-
like) to the fusion protein and acquisition of histone 3 lysine
79 (H3K79) methyltransferase activity (Figure 1). A number
of studies using both shRNA for DOT1L and conditional
deletion of DOT1L have recently shown that the H3K79
methyltransferase activity is critical for leukemogenesis
induced by MLL-fusion proteins [91, 92]. This has led to the
conceptofdevelopingtargetedtherapyforDOT1Linhibition
in the therapy of MLL-translocated leukemias. At the 2010
ASH meeting, investigators at Epizyme Inc. presented the
initial results from in vitro studies of the ﬁrst DOT1L
inhibitor, EPZ01 [93]. EPZ01 acts as a competitive inhibitor
of the cofactor S-adenosylmethionine (SAM), the universal
methyl donor for all enzymatic methyltransferase reactions.
Despite the ubiquity of SAM in protein methyltransferase
reactions, EPZ01 is reported to have a 500-fold selectivity
for DOT1L over other lysine histone and arginine methyl-
transferases. Consistent with this, the investigators revealed
selective killing of EPZ01 for leukemia cell lines bearing
MLL1 translocations over non-MLL rearranged cell lines.
DOT1L-inhibition appeared to downregulate H3K79me3
abundance globally and at critical loci, serving both as proof
of concept of the mechanism of activity and potentially as a
biomarker of response [93].
As mentioned earlier, MLL rearrangements are also
frequent in ALL with MLL-AF4 translocation being the
most frequent MLL rearrangement in ALL [90]. Although
two initial transgenic mouse models of MLL-AF4 fusion
gene overexpression did not result in the development of
acute leukemia, a conditional knockin model of MLL-AF4
[94] as well as a retroviral transplantation model of MLL-
AF4 [95] did result in the development of ALL. Moreover,
mice with overexpression of MLL-AF4 in the conditional
knockin model by Krivstov et al. were clearly distinguished
by increases in H3K79me3 indicating a clear link between
thepresenceofMLL-AF4fusiononcoproteinandacquisition
of increased H3K79 methyltransferase activity. In addition,
recent puriﬁcation of the MLL-AF4 complex has clearly
indicated binding of DOT1L to this complex [96]. Equally
important, use of an shRNA against DOT1L inhibited the
expression of several genes critical for MLL-AF4-mediated
oncogenesis in the MLL-AF4-conditional knockin model
underscoring the potential importance of DOT1L inhibition
in the therapy of ALL with MLL-AF4 rearrangement [94].
One key question which must be further addressed in
the preclinical development of DOT1L-targeted therapy is
the question of potential adverse ramiﬁcations of DOT1L
inhibition. Jo et al. recently reported that mice bearing
conditional disruption of DOT1L-developed pancytopenia
and failure of hematopoietic homeostasis revealing a critical
role of DOT1L in normal hematopoiesis [91]. At the same
meeting, Bernt et al. also developed a conditional deletion
model of DOT1L in vivo using Vav-Cre technology for
DOT1L deletion in the adult hematopoietic and endothelial
cells but also in the germline [92]. DOT1L−/− mice in this
system were born at Mendelian rations and with blood
counts at lower border of normal range. In addition, cardiac-
speciﬁc deletion of DOT1L resulted in increased mortality
in mice due to cardiac dysfunction which closely resembled
human dilated cardiomyopathy [97]. Interestingly, Nguyen
et al. further discovered that DOT1L is downregulated in
patients with idiopathic dilated cardiomyopathy, and the
cardiac phenotype in mice could be rescued by expression
of dystrophin [97]. Further characterization of these mouse
models and use of DOT1L inhibitors in preclinical in vivo
testing will hopefully clarify the potential utility and safety of
this very promising new therapeutic strategy.
Development of other speciﬁc inhibitors of histone
methyltransferases holds promise in myeloid leukemias. The
challengesforthisprospecthavebeentwofold:(1)knowledge
of the genome-wide and locus-speciﬁc eﬀects of histone
modiﬁcations due to direct genetic abnormalities found
in myeloid leukemia patients has been less clear for the8 Advances in Hematology
Table 1: Translocations directly aﬀecting histone modifying enzymes or recruitment of histone modifying enzymes in patients with myeloid
malignancies.
Gene Eﬀects of translocation on histone posttranslational modiﬁcations
MLL1
MLL1 normally serves as an H3K4 methyltransferase. MLL-AF4, MLL-AF9, MLL-AF10, and MLL-ENL
translocations result in loss of the SET domain and recruitment of DOT1L binding resulting in acquisition of
H3K79 methyltransferase activity.
CBP
The histone acetyltransferase CBP has been reported to undergo translocation with MOZ in AML. This results in
the disruption of CBP’s normal acetyltransferase activity and also in recruitment of CBP to MOZ-regulated gene
promoters. MOZ also contains a putative acetyltransferase domain which may be aﬀected in this translocation.
CBP is also an occasional translocation partner with MLL1.
NSD1
The H3K36 methyltransferase NSD1 has been rarely reported to undergo translocation with NUP98 in AML. This
translocation does not abrogate H3K36 methyltransferase activity of NSD1 but rather promotes aberrant H3K36
methylation at speciﬁc loci which promotes leukemogenesis.
P300
The histone acetyltransferase p300 is an occasional translocation partner with MLL1 in AML. This translocation
preserves the majority of the coding sequence of p300, and the direct transcriptional and histone eﬀects of this
translocation are not well characterized. Interesting p300- and CBP-MLL translocations appear to be signiﬁcantly
associated with therapy-related AML rather than de novo AML suggesting a potential diﬀerence in the
pathogenesis of these 2 subtypes of AML.
AML1
Translocations involving AML1 are characteristic of a proportion of patients with core-binding factor leukemias.
Normally the C terminus of AML1 interacts with the histone acetyltransferase p300 and recruits p300 to speciﬁc
loci bound by the N terminus of AML1. However, in the common translocation t(8;21)(q22;q22), the C terminus
of AML1 is lost and replaced with the C terminus of ETO which attracts a corepressor complex with histone
deacetylase activity (N-CoR/Sin3/HDAC complex).
RARα
The characteristic translocation of acute promyelocytic leukemia, t(15;17)(q21;q21) fuses PML with RARα.
Recently it has been demonstrated that one of the critical aspects of PML-RARα-induced oncogenesis is aberrant
downregulation of histone H3 acetylation by the PML-RARα fusion protein. Normally, in the presence of its
ligand retinoic acid, RARα functions as a transcriptional activator. However, when ligand is not present, RARa
functions as a transcriptional repressor through recruitment of HDACs. The PML-RARα fusion protein results in
constitutive HDAC activity and aberrant target gene repression. Pharmacologic doses of ATRA appear to greatly
increase histone H3 acetylation, and this, in part, serves to reverse some of the oncogenic eﬀects of the PML-RARα
fusion protein.
majority of non-MLL translocated patients. For instance,
loss-of-function mutations in the H3K27 methyltransferase
EZH2 has been recently found in patients with MDS and
primary myeloﬁbrosis [69–71]. At the same time, loss of
the H3K27 demethylase UTX has also been suggested to
occur in some of the same disorders making the rationale
for targeted changes aﬀecting H3K27 methylation hard to
understand [98]. (2) In addition, from a drug development
standpoint, potent and selective inhibitors of histone protein
methyltransferases have only recently begun. One strategy
mentioned earlier is the development of small-molecule
inhibitors of the SAM-binding pocket, a universal feature
of protein methyltransferase somewhat analogous to the
targeting of the ATP-binding pockets of protein kinases. In
fact, the ﬁrst selective and potent protein methyltransferase
inhibitor was recently reported using this strategy [99]. This
molecule serves to inhibit the arginine methyltransferase
CARM1, a protein overexpressed and thought to be impor-
tant in the pathogenesis of prostate and breast carcinomas
[100, 101]. Although empiric use of these medications
in early-phase clinical trials has been utilized previously
with some success, in-depth characterization of histone
posttranslational modiﬁcations in patients with MDS/AML
may shed light on rational strategy for speciﬁc histone
methyltransferaseinhibitionasatherapeuticstrategyinthese
disorders.
5. Conclusion
The exciting discovery of new genetic abnormalities in
patients with myeloid malignancies holds the promise for
furthering our understanding of the pathogenesis of these
disorders but also in reﬁning our risk stratiﬁcation and
therapeutic management of patients. As highlighted here, a
series of studies have rapidly suggested that mutations in
TET2, IDH1/2,a n dDNMT3a will likely reﬁne our current
prognosticationofpatientswithAMLifborneoutrepeatedly
in large prospective trials of AML patients. Moreover,
given the suggested eﬀects of these genetic abnormalities
on DNA methylation, the potential importance of these
mutations on aﬀecting response to DNMTIs will need
to be more thoroughly investigated. The eﬀects of the
recurrent DNMT3a R882 mutation will particularly need
to be scrutinized given its frequency and the fact that it
is always present as a heterozygous mutation. Furthering
our understanding of the speciﬁc altered epigenetic marks
placed by genetic abnormalities in MDS/AML patients is
criticalasitmayresultinthedevelopmentofnovelepigeneticAdvances in Hematology 9
targeted therapeutics. The clearest example of this currently
is the exciting development of DOT1L inhibitors for MLL-
translocated leukemias described here. Further characteri-
zation of DOT1L deﬁciency/inhibition in a variety of in
vivo models is greatly anticipated. Moreover, development
of additional protein methyltransferase inhibitors is likely
forthcoming and prompts for greater understanding of the
epigenetic alterations present in patients with MDS and
AML.
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